Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Mister E who wrote (7694)	2/11/2000 6:09:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

NEW YORK -(Dow Jones)- Shares of biotechnology company Cytogen Corp. soared to a 52-week high for the second straight session Friday as enthusiasm for the industry's proteomics sector continued to drive the stock. Nasdaq-listed shares of Cytogen (CYTO, news, msgs) touched a 52-week high of $14.313 in heavy trading - surpassing the previous high of $11.125 set on Thursday - as investors worked to lift the value of the Cambridge, Mass.-based company's stock to a level more in line with its peers, according to Wayne Hummer Investments analyst Michael Becker. Also, the high trading volume and number of block trades suggest institutions have gained interest in Cytogen's stock. Proteomics, the study of the interaction of proteins in the human body, is a discipline directly tied to the development of treatments for disease. It employs knowledge of protein creation derived from genomics, the study of genes. Investors are pleased by the rapidity with which Cytogen is building its database of protein interactions and are reassessing the company's value, Becker said. While the analyst doesn't cover Cytogen for his firm, he publishs analyses on the company as the editor of the "Beck On Biotech" newsletter. Cytogen is moving faster than the competition in the race to map protein interactions. Though the company wouldn't disclose how many proteins it has mapped so far, it has said its system will be able to log 200,000 protein interactions a month by mid-2000. By comparison, the database of rival CuraGen Corp. contains descriptions of more than 10,000 interactions, while Myriad Genetics Inc.'s database contains about 50,000 and is growing by 75 proteins a day, according to the Feb. 4 issue of "Beck on Biotech." "There's a rather large disparity between where CuraGen and Cytogen are valued" in light of that information, said Becker. "That's what people may be focusing on." "If Cytogen is tenfold quicker, that's obviously worth a premium or parity," he added. CuraGen (CRGN, news, msgs) hit a 52-week high of $179 a share in frenzied trading Thursday following news it had completed a protein interaction map for an entire genome, which will help in the process of identifying the protein interactions within the human genome. The news sparked a rally throughout the proteomics sector, carrying shares of Cytogen and Myriad Genetics (MYGN) higher. CuraGen has a market capitalization of about $2.6 billion, based on Thursday's closing price of $163.563 a share and the company's 15.9 million shares outstanding. By contrast, Cytogen - which has 70.4 million shares outstanding - has a market capitalization of $893.2 million. +++++++++++++ WOW! If this is real, no wonder the volume and price has rocketed up. PLENTY of room to run. Jim

To: Mister E who wrote (7694)	2/11/2000 6:36:00 PM
From: Paul A	Respond to of 8116

Give it a few days to consolidate.. alot of shorts are hitting it now, and technically its not a bad short right here.. Let them take it back to 8-10, and thats where the fun will start.. I see CYTO well over 20 in the next month or two.. The day has arrived!! I only trade stocks.. but I have been watching CYTO since I started using s/i ages ago.. did alot of trading from 3/4- 1 1/2.. lost interest until this latest break out.. I have my buy limit in just above 15.. congrats to all of you long termers! it really paid off this time

To: Mister E who wrote (7694)	2/12/2000 8:09:00 PM
From: BlueCrab	Read Replies (1) \| Respond to of 8116

Bern, glad you held those shares close. Looks like the ABCs of biotech are gonna include their C again. This is rapidly approaching OOH status. 44 million shares in two days?